Roivant Sciences (ROIV) FCF Margin (2020 - 2026)
Roivant Sciences' (ROIV) quarterly FCF Margin came in at 18629.4% in Q2 2026, down 902489.0% on a YoY basis from N/an in Q2 2025, and down 80.18% quarter-over-quarter from 10339.36% in Q4 2025.
Powered by 
Analysis
Roivant Sciences (ROIV) FCF Margin (2020 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has reported FCF Margin for 7 consecutive years, with 18629.4% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 902489.0% year-over-year to 18629.4%; the trailing twelve-month figure through Jun 2026 stood at 11572.32% (down 786036.0% YoY), and the FY2026 full-year result was 9183.51%, down 626399.0% from the prior year.
- FCF Margin declined to 18629.4% in Q2 2026 per ROIV's latest filing, from 10339.36% in the prior quarter.
- Across five years, FCF Margin topped out at 1157.67% in Q2 2023 and bottomed at 18629.4% in Q2 2026.
- Historically, FCF Margin has averaged 6252.93% across 5 years, with a median of 5392.05% in 2023.
- The sharpest annual moves came in 2023 and 2026: FCF Margin soared 485161 bps in 2023, then tumbled 902489 bps in 2026.
- Over 5 years, FCF Margin stood at 1992.02% in 2022, then tumbled by 39 bps to 2776.53% in 2023, then retreated by 12 bps to 3121.88% in 2024, then sank by 231 bps to 10339.36% in 2025, then slumped by 80 bps to 18629.4% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 18629.4%, 10339.36%, and 12317.76% for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.09 Bn | 193.10 Bn | 7.24 Bn | 34.70% |
| 2 | Gilead Sciences | 179.68 Bn | 176.50 Bn | 6.22 Bn | 44.00% |
| 3 | Vertex Pharmaceuticals | 131.39 Bn | 123.54 Bn | 2.84 Bn | 30.39% |
| 4 | Regeneron Pharmaceuticals | 81.79 Bn | 73.79 Bn | 3.93 Bn | 13.35% |
| 5 | Argenx Se | 61.15 Bn | 55.97 Bn | 1.37 Bn | - |
| 6 | Moderna | 53.35 Bn | 48.21 Bn | 52.00 Mn | -388.28% |
| 7 | Alnylam Pharmaceuticals | 33.40 Bn | 30.10 Bn | 992.69 Mn | 22.62% |
| 8 | Biogen | 31.66 Bn | 30.38 Bn | 1.96 Bn | 14.91% |
| 9 | Roivant Sciences | 29.14 Bn | 29.14 Bn | 1.16 Mn | -18,629.40% |
| 10 | Insmed | 27.69 Bn | 26.53 Bn | 358.27 Mn | -22.35% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -18,629.40% |
| Dec 31, 2025 | -10,339.36% |
| Sep 30, 2025 | -12,317.76% |
| Jun 30, 2025 | -9,604.52% |
| Dec 31, 2024 | -3,121.88% |
| Sep 30, 2024 | -5,984.40% |
| Jun 30, 2024 | -2,425.46% |
| Dec 31, 2023 | -2,776.53% |
| Sep 30, 2023 | -5,392.05% |
| Jun 30, 2023 | -1,157.67% |
| Dec 31, 2022 | -1,992.02% |
| Sep 30, 2022 | -1,537.79% |
| Jun 30, 2022 | -6,009.28% |
| Dec 31, 2021 | -1,175.42% |
| Sep 30, 2021 | -881.94% |
| Jun 30, 2021 | -1,855.32% |
| Dec 31, 2020 | -3,146.45% |
| Jun 30, 2020 | -7,073.16% |